Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Coliat · SciRah

Researcher profile · Semantic Scholar

P. Coliat

Share profile

P. Coliat — researcher profile on SciRah

h-index: 10
Works: 32
Citations: 253

Most-cited papers

Optimal Physicochemical Properties of Antibody–Nanoparticle Conjugates for Improved Tumor Targeting
V. Mittelheisser, P. Coliat, E. Moeglin, L. Goepp +4 more
2022Advances in Materials35 citations Open access
Semantic Scholar
Human Papillomavirus-related tumours of the oropharynx display a lower tumour hypoxia signature.
Elodie Hanns, S. Job, P. Coliat, C. Wasylyk +9 more
2015Oral Oncology32 citations Open access
Semantic Scholar
A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53.
V. Vidimar, C. Licona, R. Cerón-Camacho, E. Guérin +11 more
2019Cancer Letters30 citations
Semantic Scholar
A Combination of Native LC-MS Approaches for the Comprehensive Characterization of the Antibody-Drug Conjugate Trastuzumab Deruxtecan.
E. Deslignière, H. Diemer, Stéphane Erb, P. Coliat +4 more
2022Frontiers in Bioscience23 citations Open access
Semantic Scholar
Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC
P. Coliat, Ludivine Ramolu, J. Jégu, C. Gaiddon +2 more
2019Cancers18 citations Open access
Semantic Scholar
[Mechanisms of pharmacokinetic drug-drug interactions].
D. Levêque, J. Lemachatti, Y. Nivoix, P. Coliat +4 more
2010La Revue de medecine interne18 citations
Semantic Scholar
Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation
P. Mertes, O. Collange, P. Coliat, M. Banerjee +23 more
2021Journal of Controlled Release16 citations Open access
Semantic Scholar
Influence of pneumatic transportation on the stability of monoclonal antibodies
P. Coliat, Stéphane Erb, Hélène Diemer, D. Karouby +7 more
2023Scientific Reports12 citations Open access
Semantic Scholar
Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients
H. Carinato, M. Burgy, Régine Ferry, C. Fischbach +14 more
2021Frontiers in Oncology11 citations Open access
Semantic Scholar
Toward Clinical Transfer of Tumor‐Targeted Ultrasmall Inorganic Nanoparticles
Léna Carmès, Mainak Banerjee, P. Coliat, S. Harlepp +4 more
2023Advances in Therapy10 citations Open access
Semantic Scholar
Is antihistaminergic H2 really useful in prevention of hypersensitivity induced by paclitaxel?
F. Slimano, P. Coliat, J. Perotin, Juliette Vella-Boucaud +2 more
2016Supportive Care in Cancer7 citations Open access
Semantic Scholar
Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer
C. Borel, O. Regnier-Gavier, H. Carinato, S. Guihard +15 more
2018OncoTarget6 citations Open access
Semantic Scholar
TROIKA‐1: A double‐blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU‐Herceptin® and US‐Herceptin® in healthy male subjects
M. Demarchi, P. Coliat, K. Mclendon, Jocelyn Chung Shii Hii +9 more
2021Pharmacology Research & Perspectives5 citations Open access
Semantic Scholar
166MO A phase III trial to compare the efficacy, safety, pharmacokinetics and immunogenicity of HD201 to trastuzumab in HER2+ early breast cancer patients (TROIKA)
P. Xavier, C. S. Hii, K. Mclendon, P. Feyaerts +8 more
20205 citations Open access
Semantic Scholar
Oncology Pharmacy Practice: Key insights, challenges, and perspectives - A position paper from the French Society for Oncology Pharmacy (SFPO).
F. Ranchon, F. Slimano, I. Borget, M. Boulin +14 more
2025Annales Pharmaceutiques Françaises4 citations
Semantic Scholar
Clinically Translatable Transcrocetin Delivery Platform for Correction of Tumor Hypoxia and Enhancement of Radiation Therapy Effects.
Marie-Charlotte Diringer, P. Coliat, Clélia Mathieu, Nina Laurent +13 more
2023Small4 citations Open access
Semantic Scholar
A propensity score–weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer
H. Bischoff, C. Bigot, F. Moinard-Butot, C. Pflumio +13 more
2022Breast Cancer Research and Treatment3 citations
Semantic Scholar
A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab
M. Demarchi, P. Coliat, P. Barthélémy, R. Schott +12 more
2021PLoS ONE3 citations Open access
Semantic Scholar
Protective role of melatonin in breast cancer: what we can learn from women with blindness
C. Minella, P. Coliat, S. Amé, K. Neuberger +3 more
2021Cancer Causes and Control3 citations
Semantic Scholar
Establishing analytical and clinical similarity between HD201 and herceptin.
J. Hii, X. Pivot, K. Mclendon, K. Chan +9 more
20203 citations
Semantic Scholar
Comparative Preclinical Evaluation of Tuznue Versus Referent Herceptin: A Registered Trastuzumab Biosimilar
H. Bischoff, Neil K. O’Connor, Jamie Kim, B. Popescu +10 more
2025Drugs in R&D2 citations Open access
Semantic Scholar
Weekly paclitaxel (P), carboplatin (CP) plus pembrolizumab (PMB) as first-line treatment of recurrent or metastatic (R/M) or locally very advanced (LVA) head and neck squamous cell carcinoma (HNSCC): A retrospective study in 39 patients (pts).
C. Borel, H. Carinato, C. Pflumio, E. Poprawa +7 more
2024Journal of Clinical Oncology1 citations
Semantic Scholar
Clinical validation of pneumatic transportation systems for monoclonal antibodies
P. Coliat, Stéphane Erb, H. Diemer, D. Karouby +6 more
2023medRxiv1 citations Open access
Semantic Scholar
930P Weekly paclitaxel, carboplatin and cetuximab (PCC) as first-line treatment of recurrent and/or metastatic head & neck squamous cell carcinoma (R/M-HNSCC) for patients ineligible to cisplatin based chemotherapy
H. Carinato, M. Burgy, C. Fischbach, M. Kalish-Weindling +7 more
2020Annals of Oncology1 citations Open access
Semantic Scholar
Hydrogel confinement enables subcutaneous delivery of vesicant antibody-drug conjugates
Guillaume Jacquot, Capucine Hervy, Elies Belarouci, Adeline Gasser +25 more
2026bioRxiv0 citations Open access
Semantic Scholar
NF-κB signaling drives rapid skeletal muscle atrophy in patients with breast cancer: the cost of fighting cancer with chemotherapy.
J. Mallard, Léa Debrut, E. Hucteau, L. Somme +16 more
2026American Journal of Physiology - Cell Physiology0 citations Open access
Semantic Scholar
Considering robotic production of injectable anti-cancer drugs? Think ahead!
T. Martin, Assia Mitha, Enzo Grassi, Romain Desmaris +3 more
2025Journal de Pharmacie Clinique0 citations
Semantic Scholar
92P Utilizing pre-clinical and clinical pharmacokinetics data to identify novel interspecies conversion factors for the development of mAbs based on the NOAEL method
B. Popescu, H. Bischoff, A. Bendjama, T. Martin +8 more
2025ESMO Open0 citations Open access
Semantic Scholar
319P A propensity score weighted study comparing two versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer
H. Bischoff, C. Bigot, F. Moinard, C. Pflumio +13 more
2021Annals of Oncology0 citations Open access
Semantic Scholar
590P A double-blind, randomized, parallel group study to demonstrate the equivalent pharmacokinetic properties of a single intravenous dose HD201, a trastuzumab biosimilar candidate, versus EU trastuzumab and US trastuzumab
M. Demarchi, P. Coliat, J. Hii, P. Feyaerts +8 more
2020Annals of Oncology0 citations Open access
Semantic Scholar
Assessment of quality and clinical similarity (pharmacokinetic and safety) of HD204, a biosimilar of bevacizumab.
J. Hii, M. Demarchi, P. Coliat, M. Kim +10 more
20200 citations
Semantic Scholar
HD204: Analytical biocomparability and clinical trial I progression of bevacizumab.
J. Hii, X. Pivot, L. Park, M. Kim +8 more
2019Journal of Clinical Oncology0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Demarchi×13
Invite
M. Demarchi — researcher profile on SciRah
X. Pivot×12
Invite
X. Pivot — researcher profile on SciRah
L. Park×9
Invite
L. Park — researcher profile on SciRah
A. Detappe×7
Invite
A. Detappe — researcher profile on SciRah

×7

Invite

P. Feyaerts — researcher profile on SciRah

Invite

F. Ang — researcher profile on SciRah

Invite

M. Derde — researcher profile on SciRah

Invite

A. Jung — researcher profile on SciRah

Xavier Pivot×5

Invite

Xavier Pivot — researcher profile on SciRah

Invite

F. Deforce — researcher profile on SciRah

Invite

M. Kim — researcher profile on SciRah

Stéphane Erb×4

Invite

Stéphane Erb — researcher profile on SciRah